A trial to determine whether a tapering regime to reduce high dose opioids for people with persistent non-cancer pains work better with or without additional behavioural support

A feasibility study of a Behavioural Intervention for Opioid Reduction (BIOR) for chronic non-cancer pain patients in primary care

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN30201337

Enrollment

100

Registered

2022-06-07

Start date

2022-05-18

Completion date

Unknown

Last updated

2024-08-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Opioid reduction in chronic non-cancer pain patients Musculoskeletal Diseases

Interventions

Participants are randomised to one of two groups using a random number sequence created using an online tool. ‘Taper Group’- care as usual and continue to taper opioid medication by a tailored fortni

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Current participant inclusion criteria as of 07/07/2022: Patients: 1. Aged 18 years old or over 2. Diagnosed with chronic non-cancer pain 3. Taking prescribed high dose opioids (>50 mg daily MED) 4. Taking opioids for more than 3 months 5. Registered at a GP practice in Kirkby. Allied Health Professionals (AHP): 1. AHPs aged 18 years or older 2. AHP currently delivering BIOR as part of the study Previous participant inclusion criteria: Patients: 1. Aged 18 years old or over 2. Diagnosed with chronic non-cancer pain 3. Taking prescribed high dose opioids (>120mg daily MED) 4. Taking opioids for more than 3 months 5. Registered at a GP practice in Kirkby. Allied Health Professionals (AHP): 1. AHPs aged 18 years or older 2. AHP currently delivering BIOR as part of the study

Exclusion criteria

Exclusion criteria: Patients: 1. Major psychiatric co-morbidity (e.g. Schizophrenia; substance abuse) - a major physical illness. 2. Contact with a pain clinic in the past 3 years 3. Aged over 75 years Allied Health Professionals (AHP): 1. Cannot establish conversation in English.

Design outcomes

Primary

Measure	Time frame
Morphine equivalent dose (MED) of opioid intake reported by the participants at baseline, monthly for 6 months and at 12 months follow-up	—

Secondary

Measure	Time frame
Self-reported questionnaire data measured at baseline, monthly for 6 months and at 12 months follow-up: 1. Pain (Brief Pain Inventory (BPI)) 2. Pain coping (Pain Coping Questionnaire (PCQ)) 3. Catastrophizing (Pain Catastrophising Scale (PCS)) 4. Stage of change (Pain Stages of Change Questionnaire (PSOCQ)) 5. Mood measured using a single item from the BPI 6. Function (Pain Self-Efficacy Questionnaire (PSEQ)) 7. Self-reported symptoms of withdrawal (Subjective Opioid Withdrawal Scale (SOWS))	—

Measure

Time frame

Self-reported questionnaire data measured at baseline, monthly for 6 months and at 12 months follow-up: 1. Pain (Brief Pain Inventory (BPI)) 2. Pain coping (Pain Coping Questionnaire (PCQ)) 3. Catastrophizing (Pain Catastrophising Scale (PCS)) 4. Stage of change (Pain Stages of Change Questionnaire (PSOCQ)) 5. Mood measured using a single item from the BPI 6. Function (Pain Self-Efficacy Questionnaire (PSEQ)) 7. Self-reported symptoms of withdrawal (Subjective Opioid Withdrawal Scale (SOWS))

—

Countries

England, United Kingdom

Contacts

Public ContactAimee Woods

a.e.woods@ljmu.ac.uk+44 7868146563

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026